Genentech Caps Cost of Cancer Drug for Some
Genentech has one of the most expensive drugs for cancer in Avastatin which can cost $50,000 per year. for colon cancer. Avastin was recently approved for lung cancer but since twice as much is needed to treat lung cancer, it would cost $100,00 per year. So it was interesting to see that Genentech is capping the cost.
Genentech Caps Cost of Cancer Drug for Some Patients - New York Times:
The drug was to be capped at $55,000 for families of certain income levels. This isn’t too big of a deal though because many patients never live long enough to reach this cap (median survival is 12.3 months). As it is apporved for more indications based on future trials, this could change especially if
Their other choice would have been to reduce the price of the drug across the board but it is likely this wold have reduced the income from Avastin more than just capping the cost. From the terms of maximizing their profits, this may be a good deal. Also, as Avastin is approved for additional indications, the potential for Avastin is enormous; some consider it to be able to reach$ 4 to $10 billion in sales per year.
Technorati Tags: Avastin, cancer drug, drug cost, Genentech, lung cancer
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
July 31st, 2007 at 2:39 am
Have you heard of the “Golden eggs” invented by that company in scotland? Apparently they have managed to genetically engineer
a flock of hens to lay eggs containing anticancer genes. It is cheap to produce and easy to extract.
I think this will be a great help to cancer suffers in the future because I know that I would never be able to afford
to get cancer treatment at the $50,000+ that they cost now.
October 9th, 2007 at 2:37 am
This blog’s information is very rich.i very like it
October 17th, 2007 at 2:11 am
I read this news and it looks a great one!